ENDONOVO THERAPEUTICS, INC.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2018 | $8.2M | $-11.4M | $379.2K |
| FY2019 | $6.9M | $-20.5M | $18.9K |
| FY2020 | $6.8M | $-14.4M | $13.4K |
| FY2021 | $7.3M | $-15.8M | $85.9K |
| FY2022 | $7.2M | $-32.2M | — |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2018 | $8.2M | $-11.4M | $379.2K |
| FY2019 | $6.9M | $-20.5M | $18.9K |
| FY2020 | $6.8M | $-14.4M | $13.4K |
| FY2021 | $7.3M | $-15.8M | $85.9K |
| FY2022 | $7.2M | $-32.2M | — |